1. Home
  2. LAC vs MPLT Comparison

LAC vs MPLT Comparison

Compare LAC & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lithium Americas Corp.

LAC

Lithium Americas Corp.

HOLD

Current Price

$3.03

Market Cap

1.6B

ML Signal

HOLD

Logo MapLight Therapeutics Inc.

MPLT

MapLight Therapeutics Inc.

HOLD

Current Price

$36.94

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LAC
MPLT
Founded
2023
2018
Country
Canada
United States
Employees
N/A
133
Industry
Metal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.3B
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
LAC
MPLT
Price
$3.03
$36.94
Analyst Decision
Hold
Strong Buy
Analyst Count
7
7
Target Price
$6.14
$32.67
AVG Volume (30 Days)
9.4M
536.2K
Earning Date
05-14-2026
05-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.47
$12.24
52 Week High
$10.52
$40.43

Technical Indicators

Market Signals
Indicator
LAC
MPLT
Relative Strength Index (RSI) 26.61 57.01
Support Level N/A $26.20
Resistance Level $4.04 $40.43
Average True Range (ATR) 0.18 2.87
MACD -0.03 -0.25
Stochastic Oscillator 14.71 47.08

Price Performance

Historical Comparison
LAC
MPLT

About LAC Lithium Americas Corp.

Lithium Americas Corp is a Canadian-based resource and materials company focused on developing, building and operating lithium deposits and chemical processing facilities. The company also holds investments in Green Technology Metals Limited (GT1) and Ascend Elements, Inc. (Ascend Elements), and exploration properties in the U.S. and Canada. The company's flagship asset is Thacker Pass, a sedimentary-based lithium deposit located in the McDermitt Caldera in Humboldt County, in northern Nevada (Thacker Pass or the Project). The company operates in only one operating segment and one geographical segment.

About MPLT MapLight Therapeutics Inc.

MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.

Share on Social Networks: